Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 54 articles:
HTML format



Single Articles


    July 2022
  1. SACHDEVA A, Hart CA, Kim K, Tawadros T, et al
    Non-canonical EphA2 activation underpins PTEN-mediated metastatic migration and poor clinical outcome in prostate cancer.
    Br J Cancer. 2022 Jul 22. pii: 10.1038/s41416-022-01914.
    PubMed     Abstract available


    June 2022
  2. TRUJILLO B, Wu A, Wetterskog D, Attard G, et al
    Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges.
    Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01881.
    PubMed     Abstract available


    May 2022
  3. NAIR-SHALLIKER V, Bang A, Egger S, Yu XQ, et al
    Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study.
    Br J Cancer. 2022 May 24. pii: 10.1038/s41416-022-01827.
    PubMed     Abstract available


  4. SALMINEN JK, Mehtola A, Talala K, Taari K, et al
    Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer.
    Br J Cancer. 2022 May 3. pii: 10.1038/s41416-022-01817.
    PubMed     Abstract available


    April 2022
  5. OWARI T, Tanaka N, Nakai Y, Miyake M, et al
    5-Aminolevulinic acid overcomes hypoxia-induced radiation resistance by enhancing mitochondrial reactive oxygen species production in prostate cancer cells.
    Br J Cancer. 2022 Apr 1. pii: 10.1038/s41416-022-01789.
    PubMed     Abstract available


  6. RASMUSSEN M, Fredsoe J, Tin AL, Vickers AJ, et al
    Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence.
    Br J Cancer. 2022;126:1004-1009.
    PubMed     Abstract available


    March 2022
  7. SALBERG UB, Skingen VE, Fjeldbo CS, Hompland T, et al
    A prognostic hypoxia gene signature with low heterogeneity within the dominant tumour lesion in prostate cancer patients.
    Br J Cancer. 2022 Mar 24. pii: 10.1038/s41416-022-01782.
    PubMed     Abstract available


    February 2022
  8. SLOOTBEEK PHJ, Kloots ISH, Smits M, van Oort IM, et al
    Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.
    Br J Cancer. 2022 Feb 24. pii: 10.1038/s41416-022-01765.
    PubMed    


    January 2022
  9. RANA S, Valbuena GN, Curry E, Bevan CL, et al
    MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data.
    Br J Cancer. 2022 Jan 12. pii: 10.1038/s41416-021-01677.
    PubMed     Abstract available


    December 2021
  10. NYBERG T, Tischkowitz M, Antoniou AC
    BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis.
    Br J Cancer. 2021 Dec 28. pii: 10.1038/s41416-021-01675.
    PubMed     Abstract available


  11. MCHUGH J, Saunders EJ, Dadaev T, McGrowder E, et al
    Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups.
    Br J Cancer. 2021 Dec 18. pii: 10.1038/s41416-021-01669.
    PubMed     Abstract available


  12. SLOOTBEEK PHJ, Kloots ISH, Smits M, van Oort IM, et al
    Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.
    Br J Cancer. 2021 Dec 15. pii: 10.1038/s41416-021-01663.
    PubMed     Abstract available


    November 2021
  13. SRIVASTAVA SK, Khan MA, Anand S, Zubair H, et al
    MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer.
    Br J Cancer. 2021 Nov 26. pii: 10.1038/s41416-021-01641.
    PubMed     Abstract available


  14. WEN YC, Liu CL, Yeh HL, Chen WH, et al
    PCK1 regulates neuroendocrine differentiation in a positive feedback loop of LIF/ZBTB46 signalling in castration-resistant prostate cancer.
    Br J Cancer. 2021 Nov 24. pii: 10.1038/s41416-021-01631.
    PubMed     Abstract available


  15. RAMIREZ-GARRASTACHO M, Berge V, Line A, Llorente A, et al
    Potential of miRNAs in urinary extracellular vesicles for management of active surveillance in prostate cancer patients.
    Br J Cancer. 2021 Nov 22. pii: 10.1038/s41416-021-01598.
    PubMed     Abstract available


  16. RAMIREZ-GARRASTACHO M, Bajo-Santos C, Line A, Martens-Uzunova ES, et al
    Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research.
    Br J Cancer. 2021 Nov 22. pii: 10.1038/s41416-021-01610.
    PubMed     Abstract available


  17. HATANO K, Yoneyama T, Hatakeyama S, Tomiyama E, et al
    Simultaneous analysis of serum alpha2,3-linked sialylation and core-type fucosylation of prostate-specific antigen for the detection of high-grade prostate cancer.
    Br J Cancer. 2021 Nov 20. pii: 10.1038/s41416-021-01637.
    PubMed     Abstract available


  18. NA R, Wei J, Sample CJ, Gielzak M, et al
    The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients.
    Br J Cancer. 2021 Nov 19. pii: 10.1038/s41416-021-01622.
    PubMed     Abstract available


    September 2021
  19. YU H, Xie M, Meng Z, Lo CY, et al
    Endolysosomal ion channel MCOLN2 (Mucolipin-2) promotes prostate cancer progression via IL-1beta/NF-kappaB pathway.
    Br J Cancer. 2021 Sep 21. pii: 10.1038/s41416-021-01537.
    PubMed     Abstract available


  20. KAKOURATOS C, Kalamida D, Lamprou I, Xanthopoulou E, et al
    Apalutamide radio-sensitisation of prostate cancer.
    Br J Cancer. 2021 Sep 1. pii: 10.1038/s41416-021-01528.
    PubMed     Abstract available


  21. LIU Z, Thong MSY, Doege D, Koch-Gallenkamp L, et al
    Prevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional population-based survey in Germany.
    Br J Cancer. 2021;125:877-883.
    PubMed     Abstract available


    July 2021
  22. DE GIORGI U, Sansovini M, Severi S, Nicolini S, et al
    Circulating androgen receptor gene amplification and resistance to (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial.
    Br J Cancer. 2021 Jul 31. pii: 10.1038/s41416-021-01508.
    PubMed     Abstract available


  23. ZHAO Z, Zhao S
    Reply to Comment on "miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition".
    Br J Cancer. 2021 Jul 20. pii: 10.1038/s41416-021-01493.
    PubMed    


  24. AHMAD F, Cherukuri MK, Choyke PL
    Metabolic reprogramming in prostate cancer.
    Br J Cancer. 2021 Jul 14. pii: 10.1038/s41416-021-01435.
    PubMed     Abstract available


  25. SUI Y, Hu W, Zhang W, Li D, et al
    Insights into homeobox B9: a propeller for metastasis in dormant prostate cancer progenitor cells.
    Br J Cancer. 2021 Jul 10. pii: 10.1038/s41416-021-01482.
    PubMed     Abstract available


    June 2021
  26. SJOBERG HT, Philippou Y, Magnussen AL, Tullis IDC, et al
    Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.
    Br J Cancer. 2021 Jun 21. pii: 10.1038/s41416-021-01450.
    PubMed     Abstract available


  27. LAN T, Park Y, Colditz GA, Liu J, et al
    Adolescent animal product intake in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study.
    Br J Cancer. 2021 Jun 16. pii: 10.1038/s41416-021-01463.
    PubMed     Abstract available


  28. CHEN F, Han Y, Kang Y
    Bone marrow niches in the regulation of bone metastasis.
    Br J Cancer. 2021;124:1912-1920.
    PubMed     Abstract available


    May 2021
  29. CRISTOBAL I, Santos A, Rubio J, Rojo F, et al
    Comment on "miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition".
    Br J Cancer. 2021 May 19. pii: 10.1038/s41416-021-01433.
    PubMed    


  30. WOKOLORCZYK D, Kluzniak W, Stempa K, Rusak B, et al
    PALB2 mutations and prostate cancer risk and survival.
    Br J Cancer. 2021 May 18. pii: 10.1038/s41416-021-01410.
    PubMed     Abstract available


  31. FILON M, Gawdzik J, Truong A, Allen G, et al
    Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
    Br J Cancer. 2021 May 11. pii: 10.1038/s41416-021-01398.
    PubMed     Abstract available


  32. AMADOU A, Freisling H, Jenab M, Tsilidis KK, et al
    Prevalent diabetes and risk of total, colorectal, prostate and breast cancers in an ageing population: meta-analysis of individual participant data from cohorts of the CHANCES consortium.
    Br J Cancer. 2021;124:1882-1890.
    PubMed     Abstract available


    April 2021
  33. EMOND JP, Lacombe L, Caron P, Turcotte V, et al
    Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression.
    Br J Cancer. 2021 Apr 7. pii: 10.1038/s41416-021-01376.
    PubMed     Abstract available


    February 2021
  34. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available


    January 2021
  35. ZHAO Z, Zhao S, Luo L, Xiang Q, et al
    Correction: miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition.
    Br J Cancer. 2021 Jan 13. pii: 10.1038/s41416-020-01258.
    PubMed    


    December 2020
  36. NIKHIL K, Haymour HS, Kamra M, Shah K, et al
    Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer.
    Br J Cancer. 2020 Dec 14. pii: 10.1038/s41416-020-01197.
    PubMed     Abstract available


  37. LIU S, Shen M, Hsu EC, Zhang CA, et al
    Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer.
    Br J Cancer. 2020 Dec 8. pii: 10.1038/s41416-020-01200.
    PubMed     Abstract available


  38. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available


    November 2020
  39. ZHAO Z, Zhao S, Luo L, Xiang Q, et al
    miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition.
    Br J Cancer. 2020 Nov 26. pii: 10.1038/s41416-020-01187.
    PubMed     Abstract available


    October 2020
  40. LOZANO R, Castro E, Aragon IM, Cendon Y, et al
    Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
    Br J Cancer. 2020 Oct 27. pii: 10.1038/s41416-020-01114.
    PubMed     Abstract available


  41. LI T, Liu N, Gao Y, Quan Z, et al
    Long noncoding RNA HOTAIR regulates the invasion and metastasis of prostate cancer by targeting hepaCAM.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01091.
    PubMed     Abstract available


    September 2020
  42. MOUT L, Moll JM, Chen M, de Morree ES, et al
    Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.
    Br J Cancer. 2020 Sep 29. pii: 10.1038/s41416-020-01105.
    PubMed     Abstract available


  43. WANG LP, Chen TY, Kang CK, Huang HP, et al
    BCAS2, a protein enriched in advanced prostate cancer, interacts with NBS1 to enhance DNA double-strand break repair.
    Br J Cancer. 2020 Sep 23. pii: 10.1038/s41416-020-01086.
    PubMed     Abstract available


  44. PEREZ-CORNAGO A, Fensom GK, Andrews C, Watts EL, et al
    Examination of potential novel biochemical factors in relation to prostate cancer incidence and mortality in UK Biobank.
    Br J Cancer. 2020 Sep 23. pii: 10.1038/s41416-020-01081.
    PubMed     Abstract available


  45. NASTALY P, Stoupiec S, Popeda M, Smentoch J, et al
    EGFR as a stable marker of prostate cancer dissemination to bones.
    Br J Cancer. 2020 Sep 9. pii: 10.1038/s41416-020-01052.
    PubMed     Abstract available


    August 2020
  46. HAESE A, Tin AL, Carlsson SV, Sjoberg DD, et al
    A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy.
    Br J Cancer. 2020;123:604-609.
    PubMed     Abstract available


    July 2020
  47. CONTEDUCA V, Wetterskog D, Scarpi E, Romanel A, et al
    Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer.
    Br J Cancer. 2020 Jul 16. pii: 10.1038/s41416-020-0969.
    PubMed     Abstract available


  48. NOBLE SM, Garfield K, Lane JA, Metcalfe C, et al
    The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer.
    Br J Cancer. 2020 Jul 16. pii: 10.1038/s41416-020-0978.
    PubMed     Abstract available


  49. PHILIPPOU Y, Sjoberg HT, Murphy E, Alyacoubi S, et al
    Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.
    Br J Cancer. 2020 Jul 9. pii: 10.1038/s41416-020-0956.
    PubMed     Abstract available


    June 2020
  50. LI L, Hobson L, Perry L, Clark B, et al
    Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer.
    Br J Cancer. 2020 Jun 25. pii: 10.1038/s41416-020-0951.
    PubMed     Abstract available


    May 2020
  51. FENG X, Song M, Preston MA, Ma W, et al
    The association of diabetes with risk of prostate cancer defined by clinical and molecular features.
    Br J Cancer. 2020 May 29. pii: 10.1038/s41416-020-0910.
    PubMed     Abstract available


  52. HUR J, Giovannucci E
    Racial differences in prostate cancer: does timing of puberty play a role?
    Br J Cancer. 2020 May 22. pii: 10.1038/s41416-020-0897.
    PubMed     Abstract available


  53. BUTLER EN, Kelly SP, Coupland VH, Rosenberg PS, et al
    Fatal prostate cancer incidence trends in the United States and England by race, stage, and treatment.
    Br J Cancer. 2020 May 20. pii: 10.1038/s41416-020-0859.
    PubMed     Abstract available


    September 2019
  54. ZHAO J, Giri A, Zhu X, Shrubsole MJ, et al
    Calcium: magnesium intake ratio and colorectal carcinogenesis, results from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2019 Sep 23. pii: 10.1038/s41416-019-0579.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: